HDAC6 and cystic fibrosis: The effects of pharmacological inhibition of HDAC6 usingTubA (10 μM for 24 h) on membrane cholesterol levels were alsoassessed in CF bronchial epithelial cells (CFBE) through a double-pulsetechnique.107 These experiments conclusivelydemonstrated that tubulin acetylation is a crucial pathway in pathophysiologyof several CF phenotypes and that HDAC6 inhibition holds promisingpotential as innovative therapeutic option for restoring those pathwaysto a more WT-like pattern.